Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 51 Skipping
This protocol targets a genetically defined sub-population of DMD patients whose dystrophin gene mutation makes them amenable to exon 51 skipping — a specific molecular eligibility criterion that opens a distinct, targeted treatment pathway.
Clinical Scenario
The patient has confirmed Duchenne muscular dystrophy with a mutation amenable to skipping of exon 51. This genetic profile determines eligibility for a class of therapy not applicable to the broader DMD population.
Treatment Approach (Partial Summary)
An antisense oligonucleotide (ASO) exon-skipping therapy is indicated for this population. The full regimen details — including administration schedule, monitoring, and adjunct care — are available in the complete structured protocol.
References
- Exondys 51 (eteplirsen) - An ASO indicated for the treatment of patients with DMD amenable to skipping exon 51.